PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Quetiapine - Psychosis
PAD Profile : Quetiapine - Psychosis
Keywords :
Antipsychotics, Schizophrenia, Mania, Bipolar disorder
Brand Names Include :
Seroquel, Zaluron XL, Ebesque XL, Biquelle XL, Sondate, Tenprolide XL, Mintreleq XL, Brancico XL, Atrolak XL
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
No drugs returned.
Other Indications
Additional Documents
Type
Document
Review Date
Shared Care
01 July 2018
Patient resource
01 January 2021
Committee Recommendations
Date
Committee Name
Narrative
06 June 2018
Surrey Medicines Commissioners Group
Immediate release (IR) quetiapine should be used in preference to the XL formulations as recommended by the PCN in May 2012.
Quetiapine IR should be prescribed generically. The Seroquel brand was assigned a BLACK traffic light status by the PCN in May 2017
SABP have updated (Jan 2018) a number of resources aimed at supporting the use of IR quetiapine in preference to the XL formulations - see below
A shared-care Information Sheet for prescribers can also be found below.
Where quetiapine is used in Behavioural and Psychological Symptoms of Dementia (BPSD), please see PAD page for this indication (search BPSD or see link below)
Associated BNF Codes
04. Central Nervous System
04.02.01. Antipsychotic drugs